Loading institutional data...
Loading institutional data...
Held by 524 of 5,944 reporting institutions (97th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 14%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $504M covers all $144M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~5.6% on $142M of debt.
Cash of $504M fully covers short-term debt of $4M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.06B 100.0% | $4.26B 100.0% | $3.73B 100.0% | $3.03B 100.0% | $2.63B 100.0% | $2.40B 100.0% | $2.04B 100.0% | $1.75B 100.0% | $1.60B 100.0% | $1.65B 100.0% |
| Cost of Revenue | $4.02B 79.5% | $3.38B 79.3% | $2.94B 78.9% | $2.35B 77.8% | $2.02B 76.9% | $1.87B 77.6% | $1.62B 79.6% | $1.42B 80.8% | $1.31B 82.2% | $1.34B 81.1% |
| Cost of Services | — | — | — | — | — | — | — | — | $1.50B 93.7% | $1.34B 81.1% |
| Selling, General & Admin | $269.8M 5.3% | $225.1M 5.3% | $263.0M 7.1% | $158.8M 5.2% | $151.8M 5.8% | $129.7M 5.4% | $110.9M 5.4% | $90.6M 5.2% | $74.1M 4.6% | $69.2M 4.2% |
| Total Operating Expenses | $4.63B 91.6% | $3.90B 91.6% | $3.47B 93.2% | $2.73B 90.2% | $2.37B 90.1% | $2.18B 90.7% | $1.91B 93.7% | $1.67B 95.2% | $1.56B 97.3% | $1.56B 94.4% |
| Operating Income | $425.3M 8.4% | $358.3M 8.4% | $255.4M 6.8% | $296.8M 9.8% | $260.5M 9.9% | $223.2M 9.3% | $129.2M 6.3% | $84.9M 4.8% | $43.2M 2.7% | $91.8M 5.6% |
| Interest Expense | $8.0M 0.2% | $8.3M 0.2% | $8.1M 0.2% | $8.9M 0.3% | $6.8M 0.3% | $9.4M 0.4% | $15.7M 0.8% | $15.2M 0.9% | $13.6M 0.9% | $7.1M 0.4% |
| Interest & Investment Income | $24.5M 0.5% | $28.7M 0.7% | $19.2M 0.5% | $5.0M 0.2% | — | $3.8M 0.2% | $2.6M 0.1% | $2.0M 0.1% | $1.6M 0.1% | $1.1M 0.1% |
| Other Income (Expense), net | $30.3M 0.6% | $27.8M 0.7% | $17.4M 0.5% | -$7.7M -0.3% | -$2.5M -0.1% | -$5.5M -0.2% | -$13.0M -0.6% | -$13.2M -0.8% | -$12.0M -0.8% | -$6.0M -0.4% |
| Pretax Income | $455.6M 9.0% | $386.1M 9.1% | $272.8M 7.3% | $289.1M 9.6% | $258.0M 9.8% | $217.6M 9.1% | $116.2M 5.7% | $71.7M 4.1% | $31.2M 2.0% | $85.8M 5.2% |
| Income Tax Expense | $111.4M 2.2% | $87.6M 2.1% | $62.9M 1.7% | $64.4M 2.1% | $60.3M 2.3% | $46.2M 1.9% | $24.0M 1.2% | $12.7M 0.7% | $14.2M 0.9% | $33.0M 2.0% |
| Net Income | $344.0M 6.8% | $298.0M 7.0% | $209.4M 5.6% | $224.7M 7.4% | $194.7M 7.4% | $170.5M 7.1% | $110.5M 5.4% | $92.4M 5.3% | $40.5M 2.5% | $50.0M 3.0% |
| Per Share | ||||||||||
| EPS (Basic) | $6.00 | $5.26 | $3.76 | $4.09 | $3.57 | $3.19 | $2.07 | $1.78 | $0.79 | $0.99 |
| EPS (Diluted) | $5.84 | $5.12 | $3.65 | $3.95 | $3.42 | $3.06 | $1.97 | $1.70 | $0.77 | $0.96 |
| Weighted Avg Shares (Basic) | 57.3M | 56.7M | 55.7M | 54.9M | 54.5M | 53.4M | 53.5M | 52.0M | 50.9M | 50.6M |
| Weighted Avg Shares (Diluted) | 58.9M | 58.2M | 57.3M | 56.9M | 56.9M | 55.8M | 56.0M | 54.4M | 52.8M | 52.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $14M dividends + $20M buybacks = $34M returned.
9 consecutive years of dividend increases · 5%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ENSG | $10.2B | 29.9× | 18.5× | 2.0× | 18.7% | 20.5% | 6.8% | 15.4% | 14.5% | 0.3× | 524 |
Peers = companies sharing ENSG's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 96th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 80.8 | 79.6 | 77.6 | 76.9 | 77.8 | 78.9 | 79.3 | 79.5 |
| SG&A | 5.2 | 5.4 | 5.4 | 5.8 | 5.2 | 7.1 | 5.3 | 5.3 |
| Operating Income | 4.8 | 6.3 | 9.3 | 9.9 | 9.8 | 6.8 | 8.4 | 8.4 |
| Income Tax | 0.7 | 1.2 | 1.9 | 2.3 | 2.1 | 1.7 | 2.1 | 2.2 |
| Net Income | 5.3 | 5.4 | 7.1 | 7.4 | 7.4 | 5.6 | 7.0 | 6.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ENSG: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.